Defining On-Treatment Remission in Plaque Psoriasis

作者：April W. Armstrong, George Gondo, Joseph F. Merola, Alyssa Roberts, Lourdes M. Pérez-Chada, Deepak Balak, Guy S. Eakin, Charlotte Read, Stephanie T. Le, Yasmin Gutierrez, Tina Bhutani, Andrew Blauvelt, Kristina Callis Duffin, Steven Fakharzadeh, Steven R. Feldman, Joel M. Gelfand, Dafna D. Gladman, Brad Glick, Lawrence J. Green, George Han, Jason E. Hawkes, Samuel Hwang, Nicole Johnsen, Robert E. Kalb, Leon Kircik, Richard G. Langley, Mark Lebwohl, G. Michael Lewitt, Emanual Maverakis, Ronald Prussick, Soumya M. Reddy, Cheryl F. Rosen, José U. Scher, Evan Siegel, Elizabeth B. Wallace, Jeffrey M Weinberg, Paul S. Yamauchi, Gil Yosipovitch, Wilson Liao · 发表于：JAMA Dermatology · 年份：2025 · DOI：10.1001/jamadermatol.2025.1625 · 被引用次数：11 · 研究领域：Psoriasis: Treatment and Pathogenesis、Delphi Technique in Research、Spondyloarthritis Studies and Treatments

Importance: Defining on-treatment remission in plaque psoriasis is important for benchmarking patient responses to therapies. This also helps to facilitate shared understanding, align treatment expectations, and enable more effective psoriasis management. Objective: To establish a consensus-based definition of on-treatment remission for plaque psoriasis through a multistage Delphi initiative. Evidence Review: The Remission Workgroup from the medical board and scientific advisory board of the National Psoriasis Foundation engaged various stakeholders, both US based and international, to participate in the consensus process. Following a working group meeting to determine the overall consensus approach, a systematic review of remission definitions in the current literature was performed. This review helped to inform the content of consensus materials. The consensus effort involved 2 stages: pre-Delphi interviews and surveys to inform the Delphi questions, followed by a Delphi exercise with physicians to define on-treatment remission for plaque psoriasis. Outcome measures considered included body surface area (BSA), Investigator Global Assessment (IGA), the product of the Physician Global Assessment and body surface area (PGA × BSA), and Psoriasis Area and Severity Index (PASI) score at various cutoff levels and time points. Findings: The consensus process involved 92 stakeholders, including dermatologists, rheumatologists, researchers, patients, payers, and life sciences profess...